# RETAIN (NCT02710734)

> Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02710734
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Fox Chase Cancer Center
- Conditions: Urothelial Carcinoma of the Bladder
- Interventions: Methotrexate; Vinblastine; Doxorubicin; Cisplatin; Intensity modulated radiation therapy (IMRT); Transurethral Resection of Bladder tumor; 5-FU; Mitomycin C
- Enrollment: 78
- Primary outcome: Metastasis-free survival (MFS) at 2 years.

## Indexed commentary on RETAIN so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=retain-nct02710734